<DOC>
	<DOCNO>NCT01937156</DOCNO>
	<brief_summary>The purpose study assess efficacy safety SP-01 chemotherapy-induced nausea vomiting ( CINV ) associate administration moderately highly emetogenic ( ME HE ) multi-day chemotherapy，which provide scientific reliable clinical data drug registration China .</brief_summary>
	<brief_title>A Randomized Controlled Trial SP-01 ( Granisetron Transdermal Delivery System ) Chemotherapy-induced Nausea Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<criteria>Male female age ≥ 18years Histologically and/or cytologically confirm cancer The physical status score ECOG ≤ 2 Life expectancy ≥3 month Will receive multiday ME/HE chemotherapy ( ≥2 day ) emetogenic potential level 35 In accordance indication chemotherapy basic requirement ; Peripheral Haematology : Hb ≥ 9.0 g/dL , absolute neutrophil count ≥ 1.5×10e9/L , platelet count ≥ 80×10e9/L Blood biochemistry : Total bilirubin &lt; 1.25×ULN , ALT AST ≤ 2.5×ULN ; liver metastasis , ALT AST &lt; 5×ULN , Creatinine ≤ 1×ULN , basic normal serum electrolyte ( Na , Ka , Cl , Ca ) Other important organ function normally Subjects voluntarily participate sign informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>